Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

People prescribed GLP-1 agents liraglutide (Saxenda) or semaglutide for weight loss decreased their alcohol intake by almost ...

Novo Nordisk’s Wegovy (semaglutide injection) 2.4mg has demonstrated early protection against heart disease, according to new ...

Although much remains to be done, tremendous progress has been made on the prevention and control of chronic non-communicable diseases (NCDs), with slow but steady health gains achieved for millions ...

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

Millions of women may be unknowingly living with risk factors for heart, kidney and metabolic disease—interconnected ...

For the first time ever, Guatemala is calling for the 78th World Health Assembly, taking place from May 19 to 27, 2025, to adopt a resolution that reduces the burden of non-communicable diseases ...

Novo Nordisk is collaborating with multiple telehealth organizations in an effort to increase patient access to authentic Wegovy.

CKD is one of the quietest yet most devastating diseases of our time. But it also offers a mirror showing us what’s broken in ...

We expected miracles; what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...